Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases

Oskar Ljungquist, Maria Lundgren, Elena Iliachenko, Fredrik Månsson, Blenda Böttiger, Mona Landin-Olsson, Christian Wikén, Ebba Rosendal, Anna K. Överby, Byström J. Wigren, Mattias N. E. Forsell, Jens Kjeldsen-Kragh, Magnus Rasmussen, Fredrik Kahn, and Karin Holm

Department of Translational Medicine, Clinical Infection Medicine, Faculty of Medicine, Lund University, Malmö, Sweden; Department of Infectious Diseases, Helsingborg Hospital, Helsingborg, Sweden; Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden; Skåne University Hospital, Malmö, Sweden; Department of Clinical Microbiology, University and Regional Laboratories, Lund, Sweden; Department of Clinical Science, Division of Internal Medicine, Lund University, Lund, Sweden; Department of Clinical Sciences, Division of Infection Medicine, Lund University, Lund, Sweden; Department of Clinical Microbiology, Umeå University, Umeå, Sweden

ABSTRACT

Background: Immunosuppressed patients are particularly vulnerable to severe infection from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), risking prolonged viremia and symptom duration. In this study we describe clinical and virological treatment outcomes in a heterogeneous group of patients with severe immunosuppression due to various causes suffering from COVID-19 infection, who were all treated with convalescent plasma (CCP) along with standard treatment.

Methods: We performed an observational, retrospective case series between May 2020 to March 2021 at three sites in Skåne, Sweden, with a population of nearly 1.4 million people. All patients hospitalized for COVID-19 who received CCP with the indication severe immunosuppression as defined by the treating physician were included in the study (n = 28).

Results: In total, 28 severely immunocompromised patients, half of which previously had been treated with rituximab, who had received in-hospital convalescent plasma treatment of COVID-19 were identified. One week after CCP treatment, 13 of 28 (46%) patients had improved clinically defined as a decrease of at least one point at the WHO-scale. Three patients had increased score points of whom two had died. For 12 patients, the WHO-scale was unchanged.

Conclusion: As one of only few studies on CCP treatment of COVID-19 in hospitalized patients with severe immunosuppression, this study adds descriptive data. The study design prohibits conclusions on safety and efficacy, and the results should be interpreted with caution. Prospective, randomized trials are needed to investigate this further.

KEYWORDS
Antibodies
pandemic
rituximab
SARS-CoV-2
PCR
COVID-19
convalescent plasma
immunosuppression
lymphoma
**Introduction**

In January of 2020, the World Health Organization declared the COVID-19 pandemic a public health emergency of international concern [1]. Although a minority of all persons infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need hospitalization, immunosuppressed patients are particularly vulnerable to severe infection, and risk prolonged viremia, symptom duration and recurrent infection [2,3]. Particularly persons previously treated with anti-CD20 monoclonal antibodies such as rituximab risk prolonged COVID-19 infection, and a recent French study found a mortality rate of 21% in this group of patients [2,4–7].

Currently, the optimal treatment regime for severely immunosuppressed patients suffering from prolonged or severe infection remains to be investigated. Convalescent plasma (CCP) has been used for treatment in adult hospitalized patients with COVID-19 pneumonia without clinical benefit, whereas CCP within 72 h of symptom onset could reduce the risk of developing severe disease [8–11]. In one randomized controlled study, terminated early for futility, the CCP arm had more adverse events compared to the group that received standard of care [12].

The theoretical antiviral and immunomodulatory effects of CCP are however promising and could possibly be used to reduce morbidity and mortality in severely immunosuppressed patients [13]. To date, no randomized controlled trials have been published investigating the use of CCP in this group of patients, although trials are ongoing. However, previous case series have reported a favourable clinical and virological outcome after CCP in selected groups of severely immunocompromised patients [14–18].

The aim of this study was to describe clinical and virological treatment outcomes in a heterogeneous group of patients with severe immunosuppression due to various causes suffering from COVID-19 infection, who were all treated with CCP along with standard treatment.

**Methods**

**Study design, case definition and setting**

This observational, retrospective case series included patients between May 2020 to March 2021 at three sites (Lund, Malmö and Helsingborg) in Region Skåne in the south of Sweden, with a population of nearly 1.4 million people [19]. All patients hospitalized for COVID-19 who received convalescent plasma with the indication severe immunosuppression as defined by the treating physician were included in the study. In Region Skåne, convalescent plasma was available mainly within a randomized controlled study of non-immunocompromised patients [20] but could be made available as compassionate use for patients with severe immunosuppression with inability to achieve virological clearance.

**Clinical data**

All cases were retrospectively reviewed, applying a predefined study protocol. Comorbidities were assessed according to Charlson Comorbidity Score [21]. Severe immunosuppression was defined by the treating physician and is described in the results section. Clinical improvement was defined as a difference from the day of the first plasma transfusion to day 7 after the first plasma transfusion of at least -1 point of the WHO clinical criteria [22].

In addition, CRP and temperature were registered. A mean reduction of CRP of ≥50% or a normalization of morning temperature for febrile patients to below 38°C (with a mean decrease of at least 0.5°C) between day 3–0 before plasma to day 3–7 after plasma transfusion was considered clinically significant.

Virological improvement of airway or plasma samples was defined as a positive to negative SARS-CoV2 RT-PCR result or an increase of cycle threshold (Ct)-value of ≥5 between samples obtained from the same body site (nasopharynx, sputum, or endotracheal tubes) within 7 days before and after plasma treatment. Relapse was defined as either renewed or increased clinical symptoms in combination with decreasing Ct-values from plasma or airways as defined above, or detectable SARS-CoV-2 virus by PCR from plasma or airways in patients who had previously exhibited evidence of clearing the virus. 30-day mortality was defined as all-cause mortality within 30 days from the first plasma infusion.

**Virology samples**

All samples from the respiratory tract (nasopharynx, throat, sputum, or samples from endotracheal tubes) and plasma were analyzed at the Department of Clinical Microbiology, Region Skåne by SARS-CoV2 RT-PCR. For positive samples, Ct values were obtained and only samples from the same location were compared. Several RT-PCR methods were in use by the laboratory and for determining positive or negative RT-PCR all results were
deemed reliable, whereas comparison of Ct-values were only made for samples analyzed by the same method or between methods where an evaluation of the relation of Ct-values had been performed by the laboratory (not shown). The Ct-values reported in the study were adjusted accordingly.

Plasma donors

Recruitment and selection of plasma donors, preparing of plasma and detection of neutralizing antibodies (NtAbs) were performed as previously described [20].

In total, 25 donors provided 76 units of convalescent plasma used by patients in this study. Donors had NtAbs titres between 1:40 and 1:1229 with a median value of 1:141.

Three patients in this study received plasma purchased from another regional blood centre in Sweden (Uppsala). Each of these plasma units was produced by pooling plasma collected by apheresis from 4 different donors. Individual serum samples from these donors were not available. NtAbs titres in samples from these pooled plasma units were in a range 1:32–1:39.

Statistical analyses

Continuous data were summarized as median with range and categorical data as absolute numbers and percentage. The statistical analyses were performed using IBM SPSS Statistics for Macintosh, Version 25.0. (Armonk, NY: IBM) and Prism version 7 (GraphPad).

Ethics

This study was granted ethical approval from the Swedish Ethical Review Authority, reference number 2021-00637. All patients received written information about the study with an opt-out approach of consent. No patient denied participation.

Results

Patient characteristics

In total, twenty-eight severely immunocompromised patients who had received in-hospital convalescent plasma treatment of COVID-19 were identified. None of the patients had identifiable SARS-CoV-2- antibodies prior to CCP treatment, but for two patients this had not been investigated. Baseline characteristics of the included patients are presented in Table 1.

Hospitalization and treatment

The median time from onset of symptoms to CCP treatment was 26 days (range 6–68 days) and 7 of 28 patients received CCP within 14 days of onset of symptoms. After the first dose of convalescent plasma, the median time to discharge from hospital for surviving patients was 8 days (range 2–119 days).

According to the patient records, the indication as stated by the treating physician for receiving convalescent plasma, in addition to immunosuppression, was long duration of symptoms for a majority of the patients (n = 20, 71%). Six patients were treated with CCP on the account of having risk for severe COVID-19-disease, and two patients were treated with CCP due to severe disease. Most patients received 3 doses of plasma (n = 21) and were also treated with remdesivir (n = 18), overlapping with plasma treatment in 10 patients. Corticosteroids were administered to 23 patients but was initiated within 3 days before or after plasma for 6 patients only. Details of hospitalization and treatment are presented in Table 2.

A possible adverse event was noted for one patient, who had shivers 40 min after the convalescent-plasma transfusion. The same patient received two additional convalescent-plasma transfusions during the next two days without complications.

Table 1. Patient characteristics.

| Baseline characteristics | n = 28 |
|--------------------------|--------|
| Age, median (range)      | 56 (16–84) |
| Female sex, n (%)        | 15 (54) |
| Charlson Comorbidity Index, median (range) | 2 (0–5) |
| Weight, median, (range)  | 76 (42–133) |
| BMI, (n = 20) median, (range) | 25 (21–40) |
| Underlying immunosuppressive conditions and treatments |  |
| Haematological malignancy n (%) | 13 (46) |
| Chronic lymphocytic leukaemia | 4 |
| B-cell lymphoma | 3 |
| Acute promyelocyte leukaemia | 1 |
| Myeloma | 1 |
| Waldenström’s macroglobulinemia | 1 |
| Acute lymphatic leukaemia | 1 |
| Chronic neutrophilic leukaemia | 1 |
| Leukemic mantle cell lymphoma | 1 |
| Stem cell transplantation n (%) | 1 |
| Organ transplant n (%) | 5 (18) |
| Kidney | 4 |
| Liver | 1 |
| Primary immunodeficiency n (%) | 2 (7) |
| Bruton’s agammaglobulinemia | 1 |
| Goods syndrome | 1 |
| Rituximab treatment* n (%), indication | 14 (50) |
| Multiple sclerosis | 5 |
| Haematological malignancy | 5 |
| Granulomatosis with polyangiitis (GPA) | 2 |
| Rheumatoid arthritis | 1 |
| DiGeorge’s syndrome including GLILD | 1 |

*Immunosuppressive treatment including rituximab. GLILD: granulomatous and lymphocytic interstitial lung disease.
Clinical outcome of CCP

One week after CCP treatment, 13 of 28 (46%) patients showed clinical improvement defined as a decrease of at least one point at the WHO-scale [22]. Out of these 13 patients, 8 were discharged from hospital within 1 week. For three patients (one on mechanical ventilation and two on HFNC), the WHO-scale score increased within one week, of whom 2 patients died. For twelve patients, the clinical status was unchanged according to the WHO-scale.

Of six patients receiving mechanical ventilation on day 0 one died, one was weaned to HFNC and one was weaned off oxygen therapy altogether within 7 days. Three patients remained in mechanical ventilation on day 7. Of the 13 patients with improved WHO score, 8 (62%) received concomitant remdesivir and/or corticosteroids, compared with 5 out of the 15 patients (33%) without improved score.

Of 18 febrile patients, temperatures were normalized within 7 days after CCP for 14 (78%) patients. No afebrile patient developed fever after CCP treatment (Figure 1(a)). The median CRP was reduced by $\geq 50\%$ for 15 of 20 (75%) patients with a CRP measured before and after CCP treatment (Figure 1(b)).

Nineteen (68%) of the patients improved in any of the following parameters; improved WHO-score, decreased CRP or temperature as defined above, and the absence of worsening of any of the parameters.

For three patients, additional CCP was administered during the hospitalization; one patient due to persistent fever and two patients due to sustained RT-PCR positivity for SARS-CoV-2; one of which required continued lymphoma treatment and the other with sustained need for oxygen therapy. Three patients were considered having relapse of the COVID-19. Outcome after CCP treatment is presented in Table 3. Detailed, individual level data on background, clinical characteristics and outcome are provided in Table 4.

Viral outcome of convalescent plasma-treatment

A SARS-CoV-2 PCR from the respiratory tract within 7 days before and 7 days after the CCP treatment was obtained in 14 patients; 11 of these had a negative PCR or a Ct-value increased by $\geq 5$ (3 of whom received concomitant remdesivir). In three patients the RT-PCR status remained unchanged, or the Ct value was lower (Figure 1(a)). SARS-CoV-2 PCR in plasma was analyzed in 24/28 patients at any time before treatment, and of these, 18 (75%) were positive. Immediately after convalescent plasma-treatment, SARS-CoV-2 PCR from plasma was measured in 16 patients; out of which 5 (31%) were positive and 11 (69%) were negative. For patients in whom a PCR from plasma was obtained within 7 days both before and after plasma treatment the Ct value increased by $\geq 5$ for 8 of 11 (72%) and unchanged or lower for 3 patients (27%) (Figure 1(b)). SARS-CoV-2 antibodies were analyzed within 14 days after plasma transfusion for 11 patients only. Two of these patients were positive (obtained 4 and 7 days after CCP), one with a previous negative antibody titre before transfusion and one who was not tested before.

Discussion

This observational case series of 28 patients in Region Skåne, Sweden, aimed to report clinical and virological outcomes for patients with COVID-19 and severe immunosuppression treated with complementary CCP,
in addition to standard treatment regimes. Half of the patients had previously been treated with rituximab. CCP treatment appeared safe and clinical and virological improvement was achieved in many patients, though a causal relation cannot be proven.

This study contributes with data regarding CCP treatment to immunosuppressed patients hospitalized due to COVID-19 [14–17,23,24]. In one case series of patients with protracted COVID-19 and severe B-lymphocyte depletion, all but one patient improved promptly as measured by a reduction of temperature and CRP after CCP treatment [14]. Two retrospective studies found that CCP reduced mortality and disease severity compared to a control group for patients with haematological malignancies [25,26]. In contrast to some of the previously published case series, the patients of our study had a variety of different underlying conditions or therapies causing immunosuppression. Moreover, the majority of the patients were given CCP late into the course of COVID-19 infection, after a median duration of symptoms of 26 days. However, no differences in outcome could be detected between different groups of immunosuppression or different duration of symptoms before CCP and neither could we associate patient

![Temperature](image1)

![CRP](image2)

![Ct-values of SARS CoV2 PCR from respiratory tract](image3)

![Ct-values of SARS CoV2 PCR in plasma](image4)

**Figure 1.** (a) Temperature (for patients with a temperature above 38 °C at least once within 3 days before CCP treatment), (b) CRP, (c) Ct-values of SARS CoV2 PCR from comparable respiratory tract sites. (d) Ct-values of SARS CoV2 PCR in plasma. All patients except one received CCP on 3 consecutive days.
| Patient | Sex | Age | Length | Weight | CCI | Indication | CCP | Maximum level of care | Maximal respiratory support | Anticoagulant | Corticosteroids | Remdesivir with CCP | Days to CCP | Death within 30 days | WHO-score | Change in WHO-score | Lower temp if initially febrile | Composite outcome | NtAbs mean |
|---------|-----|-----|--------|--------|-----|------------|-----|----------------------|-----------------------------|--------------|----------------|---------------------|-------------|------------------|----------|---------------------|-----------------|----------------|----------|
| 1       | W   | 49  | 168    | 82     | 0   | Protracted infection | RW  | ICU                 | No respiratory support    | Enoxaparine | No             | No                  | 52          | No               | 5        | 5                   | No                | Improvement 24 |          |
| 2       | M   | 52  | 184    | 112    | 2   | Yes          | RW  | HFNC               | No respiratory support    | Enoxaparine | Yes            | No                  | 40          | No               | 5        | 5                   | No                | Improvement 280 |         |
| 3       | M   | 36  | 77     | 0      | No  | Protracted infection and prostatic PCR positivity | RW  | ICU                 | No respiratory support    | Enoxaparine | Yes            | No                  | 31          | No               | 6        | 4                   | No                | Improvement 155 |         |
| 4       | M   | 27  | 172    | 75     | 0   | No           | RW  | ONCM               | No respiratory support    | Enoxaparine | No             | No                  | 27          | No               | 4        | 2                   | No                | Improvement 155 |         |
| 5       | M   | 27  | 95     | 0      | Yes | Protracted infection | RW  | HFNC               | No respiratory support    | Enoxaparine | Yes            | No                  | 27          | No               | 6        | 5                   | –1               | – Improvement 238 |         |
| 6       | M   | 59  | 133    | 183    | 4   | No           | ICU  | Mechanical ventilation | No respiratory support    | Enoxaparine | Yes            | No                  | 20          | Yes              | 6        | 8                   | 2                | – No change 412 |         |
| 7       | M   | 64  | 69     | 2      | Yes | Protracted infection | RW  | ONCM               | No respiratory support    | Enoxaparine | Yes            | No                  | 29          | No               | 4        | 2                   | –2               | – Improvement 205 |         |
| 8       | W   | 59  | 175    | 58     | 0   | No           | RW  | HFNC               | No respiratory support    | Enoxaparine | Yes            | No                  | 43          | No               | 5        | 4                   | –1               | – Improvement 305 |         |
| 9       | W   | 46  | 177    | 99     | 1   | No           | RW  | ICU                 | No respiratory support    | Enoxaparine | Yes            | No                  | 11          | No               | 5        | 2                   | –3               | Improvement 36  |         |
| 10      | M   | 52  | 82     | 2      | No  | Protracted infection | RW  | HFNC               | No respiratory support    | Enoxaparine | Yes            | Yes                  | 21          | No               | 6        | 5                   | –1               | Improvement 503 |         |
| 11      | W   | 55  | 55     | 3      | Yes | Yes          | RW  | No respiratory support | No respiratory support    | Enoxaparine | No             | Yes                  | 6           | No               | 4        | 2                   | –2               | Improvement 36  |         |
| 12      | M   | 71  | 176    | 57     | 3   | Yes          | RW  | ICU                 | No respiratory support    | Enoxaparine | No             | No                  | 25          | Yes              | 8        | 8                   | 0                | No Improvement 253 |         |
| 13      | M   | 68  | 163    | 57     | 1   | No           | ICU  | Mechanical ventilation | No respiratory support    | Enoxaparine | No             | Yes                  | 15          | No               | 8        | 8                   | 0                | No Improvement 138 |         |
| 14      | W   | 47  | 168    | 106    | 0   | Yes          | ICU  | Mechanical ventilation | No respiratory support    | Enoxaparine | No             | Yes                  | 15          | No               | 8        | 8                   | 0                | No Improvement 138 |         |
| 15      | M   | 52  | 56     | 1      | No  | No           | ICU  | Mechanical ventilation | No respiratory support    | Enoxaparine | Yes            | No                  | 23          | No               | 8        | 6                   | –2               | No Improvement 207 |         |
| 16      | W   | 16  | 42     | 2      | No  | Yes          | ICU  | Mechanical ventilation | No respiratory support    | Enoxaparine | Yes            | No                  | 20          | Yes              | 6        | 8                   | –2               | No Improvement 257 |         |
| 17      | W   | 78  | 168    | 69     | 2   | Yes          | RW  | HFNC               | No respiratory support    | Enoxaparine | Yes            | Yes                  | 13          | No               | 5        | 5                   | 0                | – Improvement 336 |         |
| 18      | M   | 68  | 167    | 63     | 5   | No           | ICU  | Mechanical ventilation | No respiratory support    | Enoxaparine | Yes            | Yes                  | 13          | Yes              | 8        | 10                  | 2                | – Worsening 427 |         |
| 19      | W   | 84  | 165    | 68     | 3   | No           | RW  | No respiratory support | No respiratory support    | Enoxaparine | Yes            | No                  | 40          | No               | 4        | 4                   | 0                | Yes Improvement 217 |         |
| 20      | M   | 77  | 178    | 65     | 2   | No           | RW  | HFNC               | No respiratory support    | Enoxaparine | Yes            | Yes                  | 21          | No               | 6        | 6                   | 0                | – Improvement 290 |         |
| 21      | W   | 60  | 165    | 85     | 5   | No           | RW  | ONCM               | No respiratory support    | Enoxaparine | Yes            | Yes                  | 68          | No               | 4        | 4                   | 0                | – No change 229 |         |
| 22      | M   | 74  | 175    | 79     | 2   | No           | RW  | HFNC               | No respiratory support    | Enoxaparine | Yes            | Yes                  | 30          | No               | 6        | 6                   | 0                | – No change 351 |         |
| 23      | M   | 57  | 170    | 60     | 3   | Yes          | RW  | HFNC               | No respiratory support    | Enoxaparine | Yes            | Yes                  | 40          | Yes              | 4        | 4                   | 0                | – No change 139 |         |
| 24      | W   | 68  | 165    | 87     | 3   | No           | RW  | HFNC               | No respiratory support    | Enoxaparine | Yes            | Yes                  | 39          | No               | 5        | 5                   | 0                | – No change 272 |         |
| 25      | M   | 47  | 84     | 1      | Yes | No           | ICU  | Mechanical ventilation | No respiratory support    | Enoxaparine | Yes            | Yes                  | 9           | No               | 7        | 4                   | –3               | Yes Improvement 110 |         |
| 26      | W   | 44  | 170    | 63     | 0   | Yes          | RW  | ONCM               | No respiratory support    | Enoxaparine | No             | No                  | 34          | No               | 4        | 4                   | 0                | Yes Improvement 94 |         |
| 27      | M   | 46  | 175    | 91     | 2   | No           | RW  | ONCM               | No respiratory support    | Enoxaparine | No             | No                  | 20          | No               | 4        | 2                   | –2               | Yes Improvement 517 |         |
| 28      | W   | 61  | 180    | 78     | 2   | No           | ICU  | Mechanical ventilation | No respiratory support    | Enoxaparine | Yes            | Yes                  | 8           | Yes              | 8        | 8                   | 0                | Yes Improvement 95 |         |

*From initial symptoms. Composite outcome = decrease in WHO score, temperature or CRP after CCP. ICU: intensive care unit; ILC: intermediate level care; RW: regular ward; HFNC: high flow nasal cannula; ONCM: Oxygen nasal cannula or mask; CCI: Charlson comorbidity index; W: woman; M: man.
outcome with NtAbs titres in donor plasma (data not shown). It is intriguing to speculate if the mortality could have been lower in our cohort of patients, if CCP were administered within the first week of symptoms in all patients. Early administration of monoclonal antibodies has been demonstrated to reduce the need for medical attention, a surrogate for severity of infection, in outpatient patients infected with COVID-19 [27]. For some patients in our study, CCP was administered as rescue treatment in the ICU, and was otherwise commonly used in patients with protracted COVID-19-symptoms which partly explains the long duration before CCP treatment was initiated.

The retrospective nature of this study is the major limitation, as it could result in selection bias. As we did not include a control group, we cannot rule out that the improved clinical and virological outcome is the result of a regression to the mean or other medications given. The majority of the improved patients received concomitant remdesivir and/or corticosteroids which may partly explain the results rather than the given CCP.

The selection of patients treated with CCP in this study could be of considerable importance to the 30-day mortality rate of 21% in our study since severe symptoms, protracted infection or lack of virological clearance were often the indication for clinicians to treat with CCP. This makes mortality comparisons with other studies difficult and thus has to be kept in mind in the following attempt to provide some context to the mortality rate in our study. The overall, pre-vaccine mortality of hospitalized patients with COVID-19 in Sweden was 17.4% [28]. The mortality rate of solid organ transplant recipients in Sweden was 15% for hospitalized patients [29]. Studies from other countries in haematological patients hospitalized due to COVID-19 report mortality rates of 38 and 39% [30,31].

The literature is scarce regarding mortality of rituximab-treated patients with COVID-19. Besides the French study reporting a mortality rate of 21% [7], one small study of thirteen patients (of which eight were hospitalized) reported a mortality rate of 23% [32]. One study on hospitalized haematological patients with severe COVID-19 reported a mortality rate of 54%, where all were given dexamethasone and remdesivir, and 45% also received CCP [33].

The SARS-CoV-2 PCR results from the respiratory tract of this study shows that 79% of the evaluable patients had negative or increasing Ct-values after treatment. Moreover, SARS-CoV-2 PCR from plasma immediately after convalescent plasma-treatment was negative in 69% of patients. However, not all patients could be evaluated in this manner due to missing data, which is a limitation of this study.

Further limitations of our study include small and heterogeneous study sample. The patients differ in age and have a variety of primary diagnoses and comorbidities, which could have affected clinical outcomes. No strict criteria for including patients were used.

Detectable serum antibodies against SARS-CoV2 have been reported immediately after CCP treatment [15,18] in immunocompromised patients, whereas antibodies after CCP treatment were only detected in 2 of 11 tested patients in our study though donor titres were comparable to the above-mentioned studies. However, in our study, antibodies were generally analyzed later after plasma infusion than in the previous reports and may not have detected a possibly transient higher antibody level. Another explanation for undetectable SARS-CoV2 antibodies could be possible higher viral loads causing binding and elimination of antibodies.

In analogy with CCP treatment [11], early treatment with the monoclonal antibody cocktail casirivimab/imdevimab resulted in reduced mortality in out-patients who have not mounted their own immune response [27]. Reduced mortality has also been shown in hospitalized patients who were seronegative at baseline [34]. Compared to CCP, monoclonal antibody preparations provide higher antibody titres and could, especially if given early into the course of the disease, possibly result in greater clinical benefit in immunosuppressed patients compared with CCP.

In case of development of resistance to available monoclonal antibodies, and in lower resource settings without access to monoclonal antibodies, CCP could still play a role in the treatment of COVID-19. In a future viral pandemic, early administration of CCP to patients at risk of protracted or severe infection is a safe, promising treatment regime before more specific treatment is available.

Conclusion

As one of only few studies on CCP treatment of COVID-19 in hospitalized patients with severe immunosuppression, this study adds descriptive data. The study design prohibits conclusions on safety and efficacy, and the results should be interpreted with caution. Prospective, randomized trials are needed to investigate this further.
Acknowledgements

Our sincere gratitude to the plasma donors.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This study was funded by Vetenskapsrådet [#2020-06235] to MNEF, and the Swedish governmental funds for clinical research (ALF).

ORCID

Magnus Rasmussen http://orcid.org/0000-0003-1588-5473
Fredrik Kahn http://orcid.org/0000-0001-5566-6350
Karin Holm http://orcid.org/0000-0002-8289-5949

References

[1] World Health Organization. Statement on the second meeting of the International Health Regulations 2005. Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV); 2020. Available from: https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).

[2] Kos I, Balensiefer B, Roth S, et al. Prolonged course of COVID-19-Associated pneumonia in a B-Cell depleted patient after rituximab. Front Oncol. 2020;10:1578.

[3] Luciani M, Bentivegna E, Spuntarelli V, et al. Recurrent COVID-19 pneumonia in the course of chemotherapy: consequence of a weakened immune system? J Med Virol. 2021;93(4):1882–1884.

[4] Daoussis D, Leonidou L, Kalogeropoulou C, et al. Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed. Rheumatol Int. 2021;41(10):1839–1843.

[5] Yasuda H, Mori Y, Chiba A, et al. Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections. Clin Lymphoma Myeloma Leuk. 2021;21:e810–e816.

[6] Dulery R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–944.

[7] Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419–e426.

[8] Simonovich VA, Burgos Pratx LD, Sibonha P, et al. A randomized trial of convalescent plasma in covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–629.

[9] Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470.

[10] Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020;371:m3939.

[11] Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–618.

[12] Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021;27(11):2012–2024.

[13] Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.

[14] Hueso T, Poudreux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–2295.

[15] Betrains A, Godinas L, Woei-A-Jin FJS, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192(6):1100–1105.

[16] Ormazabal Vélez I, Induráin Bermejo J, Espinoza Pérez J, et al. Two patients with rituximab associated low gamma-globulin levels and relapsed Covid-19 infections treated with convalescent plasma. Transfus Apher Sci. 2021;60(3):103104.

[17] Delgado-Fernández M, García-Gemar GM, Fuentes-López A, et al. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - three consecutive cases and review of the literature. Enferm Infecc Microbiol Clin. 2021. DOI:10.1016/j.eimc.2021.01.013

[18] Rodionov RN, Biener A, Spieth P, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Transfus Apher Sci. 2021;60(3):1100–1105.

[19] Region Skåne. Population in Skåne; 2020 [cited 2021 Jan 10]. https://utveckling.skane.se/digitala-rapporter/huga/befolkning/.

[20] Holm K, Lundgren MN, Kjeldsen-Kragh J, et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. BMC Res Notes. 2021;14:440.

[21] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.

[22] Infection W. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–e197.
[23] Fung M, Nambiar A, Pandey S, et al. Treatment of immuno-compromised COVID-19 patients with convalescent plasma. Transpl Infect Dis. 2021;23(2):e13477.

[24] Ferrari S, Caprioli C, Weber A, et al. Convalescent hyper-immune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma. 2021;62(6):1490–1496.

[25] Biernat MM, Kolasiriska A, Kwiatkowski J, et al. Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID-19. Viruses. 2021;13(3):436.

[26] Thompson MA, Henderson JP, Shah PK, et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 2021;7(8):1167.

[27] Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384(3):238–251.

[28] Strålin K, Wahlström E, Walther S, et al. Mortality in hospitalized COVID-19 patients was associated with the COVID-19 admission rate during the first year of the pandemic in Sweden. Infect Dis. 2021;1–7. DOI:10.1080/23744235.2021.1983643

[29] Søfteland JM, Friman G, von Zur-Mühlen B, et al. COVID-19 in solid organ transplant recipients: a national cohort study from Sweden. Am J Transplant. 2021;21(8):2762–2773.

[30] Sanchez-Pina JM, Rodríguez Rodríguez M, Castro Quismondo N, et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 2020;105(5):597–607.

[31] Vijenthira A, Gong YF, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892.

[32] Loarce-Martos J, García-Fernández A, López-Gutiérrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015–2021.

[33] Gupta A, Desai N, Sanjeev Chauhan P, et al. Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care Centre in India. Ann Hematol. 2021. DOI:10.1007/s00277-021-04644-3

[34] Group RC, Horby PW, Mafham M, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021. DOI:10.1101/2021.06.15.21258542